For the Nordic-Baltic PCI Study Group

Slides:

Advertisements

Similar presentations

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,

Advertisements

SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Michael.

The value of DES in unprotected left main lesions has not been evaluated by dedicated randomized clinical trials. Especially, it is not known whether currently.

Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.

Randomized Comparison of Provisional Side Branch Stenting versus a Two-stent Strategy for treatment of True Coronary Bifurcation Lesions Involving a Large.

A Prospective, Randomized, "All-Comers" Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents vs. Biocompatible Polymer-Coated Zotarolimus-Eluting.

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:

SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Jens Flensted.

A multicenter, randomized, prospective DKCRUSH-III study

Eight Months Angiographic Follow-up in Patients Randomized to Crush or Culotte Stenting of Coronary Artery Bifurcation Lesions The Nordic Bifurcation Stent.

Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,

Bifurcation Overview A comprehensive overview of Bifurcation disease, treatment options and techniques.

BIFURCATION LESIONS Dr. Tahsin.N

29th ANNUAL SCIENTIFIC SESSIONS – SCA&I

Bifurcation Stenting: A primer

DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,

M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.

As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.

TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.

The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®

Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.

Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.

AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.

Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.

FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.

LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,

DEDICATION Peter Clemmensen, Henning Kelbæk, Anne Kaltoft, Steffen Helqvist, Jens Flensted Lassen, Lene Kløvgaard, Christian J Terkelsen, Hans Henrik Tilsted,

A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.

Importance Of Proximal Angle And Interpolated Minimal Luminal Diameter In Coronary Bifurcation Lesions Bhaktha M.D. Maddhavapeddy Aditya M.D. Maddury Jyotsna.

LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,

Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)

Lisette Okkels Jensen, Per Thayssen, Henrik Steen Hansen, Evald Høj Christiansen, Hans Henrik Tilsted, Lars Romer Krusell, Anton Boel Villadsen, Anders.

Lianglong Chen MD PhD FACC

Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.

Dedicated Bifurcation Stent Technology: Implications for Everyday Practice Jens Flensted Lassen MD, PH.D., FESC The Heart Centre, Rigshospitalet University.

The GREAT Trial. The Grampian Region Early Anistreplase Trial Reference Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal.

Influence of a Pressure Gradient Distal to Implanted Bare-Metal Stent on In-Stent Restenosis After Percutaneous Coronary Intervention Lisette Okkels Jensen,

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical restenosis after coronary stenting: perspectives.

Results From the MISSION! Intervention Study Sirolimus-Eluting Stents Vs Bare-Metal Stents in Patients With STEMI : 9-Month Angiographic and Intravascular.

Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.

Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.

Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.

Χριστόδουλος Παπαδόπουλος MD, PhD, FESC

Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis Nordic–Baltic–British left main.

SORT-OUT VI A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Bioabsorbable-Polymer Biolimus-Eluting Stent in Patients.

Bifurcation Management Update:

Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial.

For the Nordic-Baltic PCI Study Group

Low restenosis rate of the NIR coronary stent: Results of the Danish multicenter stent study (DANSTENT)—a randomized trial comparing a first-generation.

ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.

Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the.

Stenting of Coronary Arteries in Non Stress/Benestent Disease

Three Years Follow Up. SORT OUT II

BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.

American College of Cardiology Presented by Dr. Stephan Windecker

REALITY: 8 month results

Follow-Up of Patients Operated on With Arterial Patch Angioplasty of the Left Main Coronary Artery Anders Jönsson, MD, Jens Jensen, MD, PhD, Arne Olsson,

Presented at ACC 2003 Late Breaking Clinical Trials

Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.

For the Nordic-Baltic PCI Study Group

SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.

Main branch restenosis at 1 year

SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Michael.

Long-term safety and efficacy of zotarolimus-eluting and sirolimus-eluting stents in routine clinical care patients 36-month follow-up in the SORT OUT.

SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.

Presented at TCT 2006.

American College of Cardiology Presented by Dr. Adnan Kastrati

The American College of Cardiology Presented by Dr. A. Abazid

Presentation transcript:

For the Nordic-Baltic PCI Study Group Eight Months Angiographic Follow-up in Patients Randomized to Crush or Culotte Stenting of Coronary Artery Bifurcation Lesions The Nordic Bifurcation Stent Technique Study Pål Gunnes, Matti Niemela, Kari Kervinen, Andrejs Erglis, Indulis Kumsars, Jens F Lassen, Michael Mæng, Jan Skov Jensen, Anders Galløe, Terje Steigen, Jan Ravkilde, Timo Makikallio, Kari Ylitalo, Inga Narbute, Evald Christiansen, Lars Krusell, Sindre Stavnes, Ulrik Abildgaard, Peter Riis Hansen, Jan Mannsverk, Thor Trovik, Per Thayssen, Steffen Helqvist, Saila Vikman, Rune Wiseth, Jens Aarøe, Leif Thuesen For the Nordic-Baltic PCI Study Group 1

Stratification at randomization CRUSH (n: 209) CULOTTE (n: 215) n: 424 (100%) Clinical Follow up, 6 months (n: 209) Clinical Follow up, 6 months (n: 215) n: 424 (100%) Stratification at randomization Scheduled Angiographic Follow up, 8 months (n: 184) Scheduled Angiographic Follow up, 8 months (n:189) n: 373 (88%) Angiographic FU available (n: 160) Angiographic FU available (n: 164) n: 324 (87%) 2

Rate of main vessel and/or side branch in-lesion diameter stenosis >50% at 8 months follow-up % 12.1 p=0.10 6.6 3

Rate of main vessel and/or side branch in-stent diameter stenosis >50% at 8 months follow-up % 10.5 p=0.046 4.5 4

in-lesion diameter stenosis >50% Rate of main vessel in-lesion diameter stenosis >50% at 8 months follow-up % p=0.19 4.7 2.0 5

in-lesion diameter stenosis >50% Rate of side branch in-lesion diameter stenosis >50% at 8 months follow-up % 9.2 p=0.10 4.5 6

Localization of in-stent restenosis at 8 months follow-up CRUSH CULOTTE 0.0% 0.0% 3.8%* 9.8%* 0.6% 2.0% * p=0.04 7

Conclusion CRUSH and CULOTTE bifurcation stenting using sirolimus eluting stents were associated with low rates of restenosis at eight months angiographic follow-up The few restenoses were primarily located in side branches treated with the CRUSH technique The CULOTTE bifurcation stenting technique was associated with a single digit restenosis rate and may be preferred in suitable bifurcation anatomies Extended follow-up needed to evaluate the safety of the investigated two-stent bifurcation techniques 8